中國寶安(000009.SZ):副總裁賀雪琴涉嫌證券市場內幕交易、被證監會立案
格隆匯7月20日丨中國寶安(000009.SZ)公佈,公司於2022年7月20日收到公司副總裁賀雪琴的通知,賀雪琴收到了中國證券監督管理委員會出具的《立案吿知書》(編號:證監立案字0282022003號),因涉嫌證券市場內幕交易,根據《中華人民共和國證券法》《中華人民共和國行政處罰法》等法律法規,決定對其立案。
此次立案調查事項僅為對賀雪琴個人的調查,不會影響公司日常的經營管理活動,其本人目前仍正常履職。
該立案調查事項的結果存在不確定性,公司將持續關注事項進展情況,並嚴格按照相關法律法規的要求及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.